Goldman Sachs analyst David Roman raised the firm’s price target on Medtronic (MDT) to $85 from $83 and keeps a Sell rating on the shares. The firm is updating its model with a roll of valuation estimates by one quarter but also notes the company’s Q3 revenue miss, the analyst tells investors in a research note. Goldman points to organic revenue growth of 4.1% slowing from 5.3% in Q1 and 5.0% in Q2. The firm adds that the key focal points for the quarter was the notable deceleration in the company’s Surgical & Endoscopy business, flu-related headwinds in Acute Care and Monitoring, and a strong uptick in Cardiac Ablation Solutions.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $91 from $90 at Baird
- Medtronic’s Strong Growth and Positive Outlook Reinforce Buy Rating Despite Challenges
- Medtronic Q3 Fiscal 2025 Financial Overview
- Medtronic’s Earnings Call Highlights Consistent Growth
- Medtronic’s Strong Profitability and Growth Prospects Earn Buy Rating from Analyst